Food and Drug AdministrationImportant note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Click here to return to FDA main menu
DonateNow
Print this Article


Approval of Multispot HIV-1/HIV-2 Rapid Test

Food and Drug Administration - December 30, 2004
Richard Klein


The Food and Drug Administration (FDA) has approved a marketing application (PMA) for the Multispot HIV-1/HIV-2 Rapid Test. This device is indicated for the detection and differentiation of circulating antibodies associated with HIV-1 and HIV-2 in human plasma and serum, as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.

The test is manufactured by Bio-Rad Laboratories, Redmond, WA.

Additional information about this approval is available on the FDA website:

www.fda.gov/cber/pmaltr/P040046L.htm - Letter - (Text)

Summary of Safety and Effectiveness - (PDF)

Label - (PDF)

Richard Klein
HIV/AIDS Program Director
Office of Special Health Issues Food and Drug Administration

041230
FD041207


SOURCE: Food and Drug Administration (FDA).

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .